Biochemical Basis of Diabetic Ketoacidosis - Lecture 3
Hormonal milieu and the initiating metabolic imbalance in DKA
Diabetic ketoacidosis (DKA) is an acute complication of type 1 diabetes mellitus characterized by insulin deficiency and excess counter-regulatory hormones, notably glucagon, adrenaline (epinephrine), and cortisol. Insulin normally acts to suppress glucagon secretion, so when insulin is low, glucagon rises. This hormonal environment leads to a critical triad: decreased insulin, increased glucagon, and elevated stress hormones, each promoting processes that raise blood glucose and mobilize energy stores. In particular, insulin deficiency removes the brake on fat breakdown, while glucagon and cortisol promote lipolysis via activation of hormone-sensitive lipase, yielding a surge of free fatty acids (FFAs) in plasma.
FFAs are liberated from triacylglycerols (TAGs) stored in adipocytes as hormone sensitive lipase hydrolyzes TAGs at the oil–water interface. The FFAs exit adipocytes, bind non-covently to serum albumin, and circulate to the liver. In hepatocytes, FFAs are activated to acyl-CoA and transported to mitochondria, where they undergo fatty acid oxidation to generate acetyl-CoA. Simultaneously, gluconeogenesis is upregulated, driven by insulin deficiency and by glucagon and cortisol, raising serum glucose. The liver thus faces a dual demand: oxidize fatty acids to acetyl-CoA and produce glucose via gluconeogenesis, consuming substrates such as oxaloacetate (an intermediate of the citric acid cycle).
Fatty acid handling after uptake by hepatocytes
Once inside hepatocytes, FFAs can follow several fates. They can be re-esterified back into TAGs or cholesterol esters for storage in the cytoplasm, or they can be re-esterified and packaged into very low-density lipoproteins (VLDLs) or stored as cholesterol esters within VLDLs. Alternatively, FFAs can be transferred into the mitochondrial matrix for β-oxidation to generate acetyl-CoA, which then feeds into downstream energy or biosynthetic pathways. Two fatty acid carriers are central here: coenzyme A (CoA) and carnitine. The fatty acid initially forms an acyl-CoA in the cytoplasm, where the sulfhydryl group of CoA serves as the attachment point. The second carrier, carnitine, is a small molecule essential for shuttling fatty acyl groups into mitochondria.
In the cytoplasm, long-chain fatty acyl-CoA cannot cross the mitochondrial inner membrane. The transfer to carnitine is mediated by carnitine acyltransferase I (CAT I). This creates fatty acyl–carnitine, which can be transported across the inner mitochondrial membrane. Inside the matrix, carnitine acyltransferase II (CAT II) transfers the fatty acyl group back onto CoA, regenerating fatty acyl-CoA for β-oxidation and releasing free carnitine back into the cytosol.
Malonyl-CoA regulation and the role of insulin
A key regulatory node linking fatty acid oxidation to cellular energy status is malonyl-CoA. Malonyl-CoA is produced from acetyl-CoA by acetyl-CoA carboxylase (ACC), using ATP and bicarbonate as cofactors, with biotin as a cofactor. The reaction is
Malonyl-CoA serves as an early intermediate in fatty acid synthesis and, importantly here, as a potent inhibitor of CPT I. Thus, high malonyl-CoA levels suppress mitochondrial uptake of fatty acids, while low malonyl-CoA relieves this blockade and promotes fatty acid entry into the matrix for β-oxidation.
Insulin promotes fatty acid synthesis via this same pathway: by driving the conversion of acetyl-CoA to malonyl-CoA, insulin increases malonyl-CoA levels, thereby inhibiting mitochondrial fatty acid uptake and oxidation. In the absence of insulin (as in DKA), intracellular malonyl-CoA levels fall, removing inhibition on CPT I and allowing accelerated transfer of fatty acids into the mitochondrial matrix for β-oxidation.
Mitochondrial transport and β-oxidation of fatty acids in DKA
The cytosolic activation of FFAs to acyl-CoA is followed by their transfer to carnitine to form fatty acyl–carnitine via CAT I, enabling entry into the mitochondrial matrix. Inside the matrix, the fatty acyl group is transferred back to CoA by CAT II. With insulin deficiency, malonyl-CoA is reduced, CPT I inhibition is lifted, and fatty acids are transported into the matrix at an enhanced rate. There, β-oxidation yields acetyl-CoA, NADH, and FADH2, feeding the electron transport chain to produce ATP and driving further metabolic responses.
The acetyl-CoA produced by β-oxidation can have two fates inside the mitochondrial matrix: it can enter the citric acid cycle (via condensation with oxaloacetate to form citrate) to drive ATP production, or it can be diverted into ketone body synthesis when oxaloacetate availability for the TCA cycle is limited by gluconeogenesis. In DKA, gluconeogenesis consumes oxaloacetate to generate glucose, depleting the oxaloacetate pool and stalling the TCA cycle. When the TCA cycle is limited, acetyl-CoA accumulates and is redirected toward ketogenesis.
The fate of acetyl-CoA: TCA cycle vs. ketogenesis
Within the mitochondrial matrix, acetyl-CoA can enter the citric acid cycle by combining with oxaloacetate to form citrate, leading to ATP production in the mitochondria. However, in DKA, oxaloacetate is diverted toward gluconeogenesis, reducing its availability for the TCA cycle. As a result, acetyl-CoA cannot efficiently feed the TCA cycle and is instead channeled into the production of ketone bodies. The essential steps are:
where acetyl-CoA units condense to form acetoacetyl-CoA, which then forms HMG-CoA and ultimately ketone bodies.
HMG-CoA is a central intermediate: although it is also used in cytosolic cholesterol synthesis, here it is used in mitochondria to generate ketone bodies. The ketone bodies derived from acetoacetate include acetoacetate itself, beta-hydroxybutyrate, and acetone as a volatile byproduct. Acetoacetate can be reduced to beta-hydroxybutyrate by beta-hydroxybutyrate dehydrogenase using NADH, or it can be decarboxylated to form acetone:
ext{Acetoacetate}
ightarrow eta ext{-hydroxybutyrate} \ ext{Acetoacetate}
ightarrow ext{acetone} + CO_2.
In DKA, the combined effect of enhanced fatty acid oxidation and impaired oxaloacetate availability shifts acetyl-CoA flux toward ketogenesis, producing excess ketone bodies that enter the bloodstream and contribute to metabolic acidosis.
Ketone bodies, gluconeogenesis, and acidosis: integrated outcomes
The metabolic cascade begins with insulin deficiency and glucagon/cortisol/adrenaline elevation, stimulating lipolysis and release of FFAs. The FFAs are transported to the liver, activated to acyl-CoA, and, due to removal of the malonyl-CoA brake, transported into mitochondria for oxidation, yielding acetyl-CoA. Gluconeogenesis is driven by amino acids and oxaloacetate consumption, which depletes a key TCA cycle intermediate and stalls the cycle. The resulting acetyl-CoA is preferentially diverted to ketone body synthesis (acetoacetate, beta-hydroxybutyrate, and acetone). Protons are generated during TAG breakdown and fatty acid oxidation, contributing to the metabolic acidosis characteristic of DKA.
Putting it together: step-by-step pathogenesis recap
- In type 1 diabetes, insulin deficiency and glucagon excess drive lipolysis via hormone-sensitive lipase, releasing FFAs into circulation bound to albumin.
- FFAs are taken up by the liver, activated to acyl-CoA, and can be stored as TAGs or cholesterol esters, or sent to mitochondria for oxidation.
- Insulin deficiency lowers malonyl-CoA and removes the CPT I blockade, increasing mitochondrial uptake of FFAs via the carnitine shuttle (acyl-CoA → acyl-carnitine via CAT I; transport; reconversion to acyl-CoA via CAT II).
- Fatty acid oxidation yields acetyl-CoA, NADH, and FADH2. Oxaloacetate is diverted to gluconeogenesis, reducing its availability for the TCA cycle.
- With limited oxaloacetate, acetyl-CoA is diverted to ketogenesis, producing acetoacetate, beta-hydroxybutyrate, and acetone.
- Ketone bodies accumulate in plasma, and protons generated during lipid breakdown and oxidation contribute to acidosis, the hallmark of DKA.
Key numerical relationships and biochemical formulas (LaTeX)
- Activation of fatty acids to acyl-CoA in the cytosol:
- Acetyl-CoA carboxylation to malonyl-CoA (rate-limiting step in fatty acid synthesis; biotin-dependent):
- Malonyl-CoA inhibits mitochondrial fatty acid uptake by inhibiting CPT I, linking lipid synthesis to suppression of oxidation when insulin is present.
- Carnitine shuttle (cytosol to matrix):
- Ketogenesis from two acetyl-CoA molecules (simplified):
- Ketone body interconversion: Acetoacetate ⇌ β-hydroxybutyrate (via NADH/NAD+), and decarboxylation to acetone:
ext{Acetoacetate}
ightarrow eta ext{-hydroxybutyrate}, \ ext{Acetoacetate}
ightarrow ext{acetone} + CO_2.